MedTrace Logo

Ketamine Anesthesia in Electroconvulsive Therapy

NCT01367119 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2013-08-08

Study results available
· View outcomes & findings →

Summary

Does the use of ketamine as the anesthetic medication in electroconvulsive therapy (ECT) accelerate the antidepressant effect of ECT?

The study hypothesis was that depressed subjects receiving ECT with ketamine as the anesthetic agent would demonstrate a faster rate of improvement, defined as lower depression ratings after the second ECT than depressed patients receiving ECT with the usual anesthetic agent.

Conditions

Interventions

DRUG

Ketamine

Subjects were dosed with approximately 1.0 mg/kg, using ketamine as anesthetic.

DRUG

methohexital

Subjects were dosed with approximately 1.0 mg/kg, using methohexital as anesthetic.

Sponsors & Collaborators

Principal Investigators

  • Keith Rasmussen, MD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2012-03-31
Completion
2012-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01367119 on ClinicalTrials.gov